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Abstract 36 
Clinical outcome of 23 patients with mixed endometrioid and serous endometrial carcinomas (mixed EEC-SC) 37 
was compared to that of pure endometrioid (EEC) and pure serous (SC) carcinomas. Hotspot mutation 38 
frequencies in KRAS, PIK3CA, PTEN and TP53 and microsatellite instability (MSI) status were determined in 39 
mixed EEC-SC, as well as in their EEC and SC micro-disected components separately, and alterations were 40 
compared to frequencies in pure EEC and SC. Relapse-free (RFS) and overall survival (OS) differed 41 
significantly between mixed EEC-SC and pure EEC and  SC, revealing that outcome of mixed EEC-SCs was 42 
intermediate to that of pure EEC and pure SC. PTEN mutations were absent in pure SC, but occurred in 20% of 43 
pure EEC, and 13% of mixed EEC-SC. In contrast, TP53 mutations were more frequent in pure SC (17%) and 44 
mixed EEC-SC (22%) than in pure EEC (2%). Mutations in mixed EEC-SC were shared by the two micro-45 
dissected components in 30 %, whereas in 35% some mutations were component-specific. Mutation analysis 46 
confirms similarities between the EEC and SC components of mixed EEC-SC with pure EEC and pure SC 47 
respectively. However, PTEN and KRAS mutations were more frequent in the SC component of mixed EEC-SC 48 
than in pure SC, while TP53 mutations were more frequent in the EEC component of mixed EEC-SC than in 49 
pure EEC. Presence of different clonal mutation pattern between EEC and SC components of mixed EEC-SC 50 
raises the possibility of divergent tumor heterogeneity or biclonal origin in some cases. 51 
Introduction 52 
In industrialized countries, endometrial carcinoma is the most frequent gynaecological cancer [1]. Although 75% 53 
of these patients are diagnosed in an early stage and have favorable outcome, near 20% of the cases will recur 54 
with dismal prognosis. Based on pathologic characteristics, the majority of the cases can be divided into two 55 
different groups, type I and type II endometrial tumors. Type I tumors correspond to endometrioid endometrial 56 
carcinoma (EEC) and present a favorable prognosis. On the other hand, type II or non-endometrioid endometrial 57 
carcinoma (NEEC) corresponds to high-grade disease and frequently correlates with increased risk for relapse 58 
and bad prognosis [2]. Serous carcinoma (SC) is the paradigm for NEEC. However, not all endometrial tumors 59 
can be included into one of the above-mentioned subtypes. Approximately 3-10% of the cases present 60 
overlapping microscopic features of two or more histologic subtypes. When one of these components is present 61 
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in at least 5% of the tumor, the tumor is diagnosed as a mixed endometrial carcinoma, mixed endometrioid and 62 
serous carcinoma (mixed EEC-SC) being the most frequent tumor type. The correct diagnosis of the second 63 
component is crucial to determine treatment options and outcome for these patients, since it has been suggested 64 
that the presence of type II component regardless of the amount might adversely affect patient outcome [3]. 65 
Conversely, other studies have shown a more favourable outcome for patients with a mixed endometrial tumor as 66 
compared to patients with a pure type II tumor [4]. 67 
The clinico-pathological and etiological aspects of mixed endometrial tumors have been poorly studied, mainly 68 
due to their relative rarity. Based on molecular analysis, it has been suggested that the NEEC component 69 
originates as a result of tumor progression from a pre-existing EEC, because frequently these tumors retain 70 
molecular alterations of typical EEC tumors [2]. Furthermore, studies investigating the mutation profile of each 71 
component individually are rare and usually report on a small number of samples (n<5) [5]. Nevertheless, these 72 
molecular analyses are crucial to gain more insight into the pathogenesis of mixed endometrial tumors, which 73 
might help in developing better prognostic indicators for mixed endometrial cancer patients. 74 
In this collaborative multicenter study, we collected a series of 23 mixed EEC-SC, assessed the prognosis of 75 
mixed EEC-SC in comparison with a previous series of pure EEC and pure SC, and performed detailed 76 
molecular analysis on the separate components by checking hot spot mutations in four genes that are frequently 77 
altered in endometrial cancer. Moreover, we also determined the microsatellite instability (MSI) status of these 78 
tumors and their separate micro-dissected components. 79 
80 
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Material and Methods 81 
Patients 82 
Since mixed EEC-SC are rare, we established a multi-center international collaboration and collected formalin-83 
fixed paraffin-embedded (FFPE) tumor tissues from 23 patients from the University Hospitals Leuven, Belgium, 84 
Arnau de Vilanova University Hospital, Lleida, Spain, and General Faculty Hospital, Prague, Czech Republic. 85 
All tumors were diagnosed as mixed EEC-SC, as they contained an endometrioid (EEC) and a serous (SC) 86 
component. In all cases, the minor component represented at least 5% of the tumor, in agreement with the more 87 
recent WHO classification [6]. The proportion of the serous component ranged from 10% to 90% (mean 52%). 88 
In order to compare survival and mutation frequencies with tumors of a single morphotype, a set of 24 pure SC 89 
and 230 pure EEC from the University Hospitals Leuven were included in the study. These tumors were 90 
genotyped in a previously published study by our group [7]. The series of 24 pure SC and 230 pure EEC were 91 
reassessed histologically to exclude mixed EEC-SC. For each case (of mixed EEC-SC, pure SC and pure EEC) 92 
clinical data (including staging, treatment and follow-up), pathology report, and paraffin-embedded blocks were 93 
available. The current study obtained the relevant IRB approval in accordance with the principles of the 94 
Declaration of Helsinki. Informed consent was obtained from each patient. All patients were subjected to similar 95 
strategies of surgical staging. EEC patients were treated according to the estimated risk of recurrence, whereas 96 
SC and mixed EEC-SC patients were treated with similar adjuvant systemic approaches. 97 
Pathology 98 
To identify the different components of each mixed EEC-SC, paraffin sections of all tumors were critically 99 
reviewed by a central group of expert pathologists (M.S, S.G. and X. M-G.). Agreement between the original 100 
and the central group diagnosis was an inclusion requirement (Figure 1). In particular, based on hematoxylin and 101 
eosin (H&E) staining andimmunohistochemical staining for p53 (tumor protein 53, serous), insulin-like growth 102 
factor 2 (IMP2; serous) and estrogen receptor (ER; endometrioid carcinoma) [8, 9], the different components 103 
were identified and a representative tumor area suitable for DNA extraction of each of the different components 104 
was selected. In some cases, the immunohistochemistry panel also included PTEN, and p16 (Figure 1B).  105 
 106 
DNA extraction and somatic oncogene profiling 107 
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After pathological examination, 1-10 FFPE slides (5-10 µm) were used for DNA extraction. Tumor tissue was 108 
macro-dissected from individual slides, under microscopic control. The different EEC and SC components from 109 
each tumor were separated before deparaffinization. After deparaffinization and tissue digestion, DNA was 110 
extracted using a phenol/chloroform protocol as described before [7]. In total, we retrieved sufficient DNA from 111 
both components of 23 mixed EEC-SC tumors. 112 
Tumors were genotyped by using the MassARRAY Compact Analyser (Sequenom Inc., San Diego, USA), as 113 
described previously [7]. Briefly, automated genotyping calls were generated using the MassARRAY RTTM 114 
software and validated by manual review of the mass spectra. Mutations in different genes mainly belonging to 115 
the PI3K/AKT/PTEN/mTOR pathway were included in the study. Hotspot mutations in PIK3CA, KRAS, PTEN, 116 
and TP53, were genotyped, respectively 21, 33, 11, and 18, somatic mutations that cover, 98%, 81%, 14%, and 117 
16% of all somatic mutations occurring in these above mentioned genes, as reported in the COSMIC (Catalogue 118 
Of Somatic Mutations In Cancer database) [10]. It is important to note that our genotyping approach was 119 
designed to identify mutations in hot spot regions, which explains the expected lower frequency of mutations in 120 
PTEN and TP53 in comparison with other series of cases which assessed the entire coding sequence of these 121 
genes. However, this approach is appropriate for a comparison between different tumors, or different 122 
components of each tumor, because for each of them the same methodology is used.  123 
To determine the microsatellite instability status (MSI) of the separate components, we used a recently 124 
established 59-marker panel based on recurrent indels in MSI tumors to identify MSI [11]. In this panel, 59 125 
recurrent indels are evaluated and when 3 or more positive markers are identified, a tumor can be categorized as 126 
MSI. 127 
Statistical analyses and correlation with clinical data 128 
Data are summarized as frequencies and percentages for categorical variables. Age at diagnosis was analysed as 129 
a binary variable (< or ≥60 years). Pearson’s chi square test was used to compare categorical variables. Kaplan 130 
Meier survival and Cox regression analyses for relapse-free survival (RFS) and overall survival (OS) were used 131 
to assess differences in clinical outcome, while correcting for age and FIGO stage. P values were two-tailed and 132 
P<0.05 was considered statistically significant. Statistical analyses were performed using SPSS software v17.0 133 
(SPSS Inc., Chicago, USA).  134 
Regarding sample size and statistical power, the series analyzed in this retrospective, observational and clinical 135 
study included clinical data and samples from 277 patients, comprising  230 EEC (83%), 24 SC (9%) and 23 136 
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mixed EEC-SC (8%).  The study achieved 80% statistical power to detect a minimal Hazard Ratio of 1.94 and 137 
2.31 units respectively for RFS and OS, using a Cox regression model to assess the differences among the three 138 
groups analyzed. 139 
 140 
Results 141 
Clinical outcome of patients with mixed EEC-SC is different from patients with pure EEC or pure SC 142 
Baseline characteristics of all patients with pure EEC, mixed EEC-SC and pure SC are given in Table 1. The 143 
median follow-up of all patients was 43 months (range, 0-142 months). Mean follow-up period was 41.3 months 144 
(range 1 to 101 months) for mixed EEC-SC, 40.8 months (range 4 to 112 months) for pure EEC, and 36.3 145 
months (range 3 to 98 months) for SC patients. Overall, 230 patients and 24 patients were diagnosed with a pure 146 
EEC or pure SC respectively, whereas 23 patients had mixed EEC-SC. Pure SC were characterized by a higher 147 
risk for recurrence and a fatal outcome (dead-of-disease, DOD) (Table 1). The number of patients with 148 
recurrence was 3 for mixed EEC-SC, 34 for pure EEC, and 11 for pure SC. The number of patients with tumor 149 
related death was 2 for mixed EEC-SC, 18 for pure EEC, and 8 for pure SC. 150 
To better assess the differences in clinical outcome between patients with mixed EEC-SC and pure EEC or pure 151 
SC, we next performed Kaplan-Meier survival analyses for relapse-free survivial (RFS) and overall survival 152 
(OS) (Figure 2A-B). These analyses showed significant differences in RFS and OS between the three patient 153 
groups (Log-Rank P<0.001). We therefore performed two different Cox regression models to assess statistical 154 
differences between the different patient groups (Table 2), with or without correcting for age and FIGO stage. In 155 
the first model using pure EEC patients as reference group, we observed that RFS and OS of only pure SC and 156 
not mixed EEC-SC were significantly different from these of pure EEC patients, also after adjustment for age 157 
and FIGO stage (Table 2). However, in the second Cox regression model using pure SC as reference group, no 158 
differences in RFS and OS were observed between mixed EEC-SC and pure SC after adjustment for age and 159 
FIGO stage (Table 2). These observations indicate that outcome of patients with mixed EEC-SC is intermediate 160 
between outcome of pure EEC and pure SC.  161 
 162 
Mutation profile of mixed EEC-SC tumors is different from pure EEC and pure SC 163 
Since clinical behaviour of mixed EEC-SC was different from pure EEC and pure SC, we next questioned 164 
whether this could be explained by a different genetic background of these tumors. Therefore, we first compared 165 
the mutation profile of mixed EEC-SC with that of pure EEC and pure SC. To this end, we selected 4 genes. 166 
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Two of them are frequently mutated in EEC (KRAS and PTEN), one is predominantly mutated in SC (TP53), 167 
while the fourth (PIK3CA) is frequently mutated in both EEC and SC. Briefly, screening of the COSMIC 168 
database [10], in combination with review of recent literature, resulted in a panel of frequent mutations in 169 
endometrial cancer that we used already in a previous study [7]. Fifty-six percent (13/23) of mixed EEC-SC 170 
tumors carried at least 1 mutation, whereas this was found in 38% (9/24) of pure SC and 47% (108/230) of pure 171 
EEC. Remarkably, mutations in PIK3CA and KRAS were more frequent in mixed EEC-SC (26%) than in pure 172 
EEC (13.5% and 17.0%) and pure SC (12.5% and 16.7%), although these differences were not significant. 173 
Mutations in PTEN were absent in pure SC whereas present in 19.6% of pure EEC and 13.0% of mixed EEC-SC 174 
(Pearson's Chi Square test P=0.047). TP53 mutations were more frequent in mixed EEC-SC (22%) and pure SC 175 
(17%) than in pure EEC (1.7%) (Pearson's Chi Square test P<0.001; Table 3). In addition to the clinical outcome 176 
data, these mutation profiles also suggest that mixed EEC-SC share characteristics of both pure EEC and pure 177 
SC.  178 
 179 
Mutation frequencies and MSI status in the separate tumor components of mixed EEC-SC tumors 180 
When studying the mutation profiles of the separate micro-dissected tumor components in more detail, we 181 
observed that mutations detected in the mixed EEC-SC were shared by the two micro-dissected components in 182 
30% (7/23) of all mixed tumors, whereas in 39% (8/23) of mixed EEC-SC tumors some mutations were 183 
component-specific. A detailed overview of the mutation patterns is given in Supplemental Table 1. Remarkably, 184 
mutation frequencies in the EEC and SC components were generally similar in both components (Table 4), but 185 
with some similarities with those found in the pure EEC and pure SC (also see Table 3). The frequency of KRAS 186 
and PTEN mutations in the EEC component of mixed EEC-SC (22% and 13%, respectively) was similar to that 187 
of pure EEC (17.0% and 19.6%), and higher than that of pure SC (13% and 0%). Moreover, the frequency of 188 
TP53 mutations in the SC component of mixed EEC-SC (17%) was similar to that of pure SC (17%), and 189 
significantly higher than that of pure EEC (1.7%). Interestingly, the SC component of mixed EEC-SC had 190 
frequent mutations in KRAS and PTEN (17% and 9%), while the EEC component of mixed EEC-SC had 191 
frequent mutations in TP53 (13%) (Table 4). Finally, we also determined the MSI status in the separate 192 
components of the tumors. Three mixed EEC-SC were MSI, in both components including the SC elements 193 
(Supplemental Table 2) 194 
 195 
Discussion 196 
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Approximately 3-10% of all endometrial carcinomas are mixed, the majority composed of EEC and SC. In 197 
current practice, which follows recent 2014 WHO criteria, the presence of only 5% of either component is 198 
considered enough to categorize an endometrial carcinoma as mixed EEC-SC. It has been suggested that when a 199 
minor part of an endometrial carcinoma is composed of SC component, the patient has the same prognosis and 200 
risk for metastases as patients with pure SC [3]. Therefore, these patients are currently treated as patients with 201 
pure SC. However, in depth studies are rare and have not included any molecular data. In the present study we 202 
analysed both clinical outcome and molecular profile of mixed EEC-SC and compared these with pure EEC and 203 
pure SC. Since there is some interobserver variability in histological typing of mixed endometrial carcinomas, all 204 
tumors in our series of cases were histologically assessed by pathologists of the contributing center and by the 205 
central pathology group. Notably, pure EEC may exhibit papillary arrangements and may be erroneously 206 
diagnosed as SC. Conversely, some pure SC may show a glandular pattern of growth and may be misinterpreted 207 
as EEC. Inappropriate interpretation of these unusual pathological patterns may lead to incorrect diagnosis of 208 
mixed EEC-SC. The consensus diagnosis was supported by the results of immunohistochemical studies. Only 209 
cases with unambiguous consensus diagnosis were included in our study. 210 
We found that survival of patients with mixed EEC-SC was not significantly different from that of patients with 211 
pure EEC or pure SC. In particular, survival of these patients was intermediate between survival of patients with 212 
pure EEC and pure SC. These observations are in contrast with those of previous studies [3], but support 213 
findings in other studies [4]. This emphasizes the importance of studies on large cohorts and strict pathologic 214 
inclusion criteria.  215 
Our clinical observations raised the question whether the molecular profile of mixed EEC-SC might be different 216 
from that of pure EEC or pure SC. Therefore we first compared the mutation profile of mixed EEC-SC with that 217 
of pure EEC and pure SC. Mixed EEC-SC showed a higher frequency of KRAS (26%) and PIK3CA (26%) 218 
mutations than pure EEC (17% and 13.5% respectively) or pure SC (13% and 17% respectively), and this was 219 
also observed in the separate components of the tumors after microdissection. This indicates that mixed EEC-SC 220 
have a higher frequency of KRAS and PIK3CA mutations, regardless of the morphological appearance of the 221 
tumor component. This result confirmed previous observations of a higher frequency of PIK3CA mutations in 222 
mixed endometrioid-non-endometrioid carcinomas (44%), in comparison with pure non-endometrioid 223 
carcinomas (21%) and low- and high-grade EEC (26% and 34% respectively) [10].  224 
By analysing the two components of mixed EEC-SC separately, we observed that these components show 225 
similarities with their corresponding pure tumor counterparts, but also some molecular ambiguities. For example, 226 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
the frequency of KRAS and PTEN mutations in the EEC component of mixed EEC-SC was comparable to that in 227 
pure EEC, whereas TP53 mutations were much more frequent than in pure EEC. Moreover, the TP53 mutation 228 
frequency in the SC component of mixed EEC-SC was comparable to that in pure SC, but a higher mutation 229 
frequency of KRAS and PTEN was observed in the SC component as compared to pure SC. These results 230 
emphasize the molecular ambiguity of the two components in mixed EEC-SC.  231 
The separate analysis of the two components of a mixed EEC-SC has –to the best of our knowledge- never been 232 
described before and sheds new light on the biology of mixed endometrial tumors. Our observation that some 233 
mutations in mixed EEC-SC are shared by both components is in agreement with a previous hypothesis, 234 
suggesting that the serous component arises from a pre-existing EEC component [2]. However, the discrepancies 235 
we observed in the mutation pattern of the two components of some mixed EEC-SC, indicates that this 236 
hypothesis can not be generalized to all mixed endometrial tumors. Assuming that early alterations during 237 
carcinogenesis are shared by different components evolving later on, we postulate that mixed EEC-SC might not 238 
invariably be monoclonal but in some cases biclonal. Discrepancies in the mutation pattern between the two 239 
components of mixed EEC-SC might also be explained by the development of molecular heterogeneity during 240 
tumor progression.  241 
Recently, the Cancer Genome Atlas Research Network (TCGA) has reported an integrating genomic 242 
characterization of endometrial carcinoma [13]. Results of this study show that by unsupervised hierarchical 243 
clustering of somatic copy number alterations 4 clusters of endometrial carcinomas emerge. One of these 244 
clusters, containing the majority of SC and mixed EEC-SC but also 12% of EEC (mainly grade 3), has a high 245 
degree of copy number alterations. More interesting, exome sequencing analsyis also revealed four groups of 246 
tumors (ultramutated, hypermutated, low copy number alterations – endometrioid, high copy number alterations 247 
– serous-like), each with a different prognosis. In this TCGA study only 13 mixed EEC-SC tumors were 248 
included, and there is no evidence that microdissection of the two components was performed. Only 62% of 249 
mixed EEC-SC had the molecular profile of serous-like tumors, emphasizing the molecular ambiguity of these 250 
tumors, which is in agreement with our results.  251 
Understanding the molecular alterations of mixed EEC-SC is not only significant for prognostic purposes, but 252 
will allow better characterization and tailoring of targeted therapy for more personalized treatment. For example, 253 
our finding that mixed EEC-SC frequently show PIK3CA mutations suggests that PI3K- as well as m-TOR 254 
inhibitors may be an attractive treatment approach for this subset of patients [13, 14].  255 
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In conclusion, we show that mixed EEC-SC tumors are molecularly ambiguous, which corresponds with 256 
outcome of patients with mixed EEC-SC intermediate between that of patients with pure EEC and pure SC. 257 
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Tables and figures 327 
Figure 1. Representative image of a mixed EEC-SC tumor (A). Representative immunohistochemical 328 
features (B). 329 
Figure 2. Kaplan-Meier survival analysis for relapse-free surivival and overall survival of pure EEC, 330 
mixed EEC-SC and pure SC endometrial cancer patients. Abbreviations: EEC, endometrioid endometrial 331 
cancer; SC: serous endometrial cancer.  332 
Table 1. Demographic and clinicopathologic characteristics of patients with pure EEC, mixed EEC-SC 333 
and pure SC. 334 
Clinical data are stratified for pure EEC, mixed EEC-SC and pure SC. Percentages are given as column %. P 335 
values of a Pearson’s Chi Square test are given. Abbreviations: EEC, endometrioid endometrial carcinoma; 336 
mixed EEC-SC: mixed endometrioid and serous carcinoma, SC: Serous carcinoma; NED; no evidence of 337 
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disease; AWED, alive with evidence of disease; DID, dead of intercurrent disease; DOD, dead of disease. 338 
Clinical variables were missing for some parameters and are indicated in the table. 339 
Table 2: Cox Regression model proportional hazards (adjusted and unadjusted) 340 
Cox regression analysis, whether or not adjusted for age and FIGO stage, was used to evaluate differences in 341 
RFS and OS in the three patient groups. In model 1, pure EEC was used as a reference, in model 2, pure SC was 342 
used as reference. Abbreviations: EEC: endometrioid endometrial cancer; SC: serous endometrial cancer 343 
Table 3. Number of pure EEC, mixed EEC-SC and pure SC carrying at least 1 mutation in the indicated 344 
genes. 345 
KRAS, PIK3CA, PTEN, and TP53, mutation frequencies respectively in pure EEC, mixed EEC-SC, and pure SC. 346 
Abbreviations: EEC, endometrioid endometrial carcinoma; Mixed EEC-SC: mixed endometrioid serous 347 
carcinoma; SC: Serous carcinoma. P values of a Pearson’s chi square test are given.  348 
Table 4. Hotspot mutation frequencies in separate components of mixed EEC-SC and pure EEC and pure 349 
SC. 350 
KRAS, PIK3CA, PTEN, and TP53, mutation frequencies respectively in pure EEC, mixed EEC-SC, and pure SC. 351 
Abbreviations: EEC, endometrioid endometrial carcinoma; Mixed EEC-SC: mixed endometrioid serous 352 
carcinoma; SC: Serous carcinoma. 353 
Supplementary Table 1. Detailed overview of all detected mutations in separate components of mixed 354 
EEC-SC. When a mutation is detected, this is indicated with 1, wild-type is indicated with 0. Colors are used to 355 
differentiate between mutations that are present in both components (green), mutations only in EEC component 356 
(yellow) and mutations only in SC component (orange). 357 
Supplementary Table 2. Overview of MSI status of the separate components of the mixed EEC-SC. MSI 358 
status was determined using the 59-marker panel recently established by Zhao ET.AL. (under revision). 359 
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 Table 1. Demographic and clinicopathologic characteristics of patients with pure EEC, mixed EEC-SC  
and pure SC.  
 
Clinical data are stratified for pure EEC, mixed EEC-SC and pure SC. Percentages are given as column %. P 
values of a Pearson’s Chi Square test are given. Abbreviations: EEC, endometrioid endometrial carcinoma; 
mixed EEC-SC: mixed endometrioid and serous carcinoma, SC: Serous carcinoma; NED; no evidence of 
disease; AWED, alive with evidence of disease; DID, dead of intercurrent disease; DOD, dead of disease. 
Clinical variables were missing for some parameters and are indicated in the table. 
 
 
 
 
Total cases analysed  Pure EEC 
n=230  
Mixed EEC-SC 
n=23 
Pure SC  
n=24 
P value 
Χ2 test 
Age  
   <60  
   ≥60  
   missing data 
 
57 (24.8%) 
173 (75.2%) 
0 
 
4 (17.4%) 
18 (78.3%) 
1 (4.3%) 
 
9 (37.5%) 
15 (62.5%) 
0 
 
0.285 
 
 
FIGO 2009 
   I-II  
   III-IV  
   missing data  
 
 
178 (77.4%) 
52 (22.6%) 
0 
 
 
16 (69.6%) 
6 (26.1%) 
1 (4.3%) 
 
 
13 (54.2%) 
10 (41.7%) 
1 (4.1%) 
 
 
0.083 
 
 
 
Lymph node involvement 
   negative nodes 
   positive nodes  
   missing data  
 
 
 
114 (49.6%) 
29 (12.6%) 
87 (37.8%) 
 
 
15 (65.2%) 
7 (30.5%) 
1 (4.3%) 
 
 
13 (54.2%) 
6 (25.0%) 
5 (20.8%) 
 
 
0.307 
 
 
 
Relapse 
   no  
   yes  
   missing data 
 
191 (83.0%) 
34 (14.8%) 
5 (2.2%) 
 
18 (78.3%) 
5 (21.7%) 
0 
 
12 (50.0%) 
11 (45.8%) 
1 (4.2%) 
 
0.001 
 
Follow up 
   NED  
   AWED  
   DID  
   DOD  
   missing data  
 
 
 
194 (84.3%) 
7 (3.0%) 
8 (3.5%) 
18 (7.8%) 
3 (1.4%) 
 
 
15 (65.2%) 
0  
3 (13.1%) 
5(21.7%) 
0 
 
 
11 (45.8%) 
3 (12.5%) 
0 
8 (33.3%) 
2 (8.3%) 
 
 
<0.001 
Table
 Table 2: Cox Regression model proportional hazards (adjusted and unadjusted) 
Relapse-Free survival Unadjusted 
hazard 
ratio 
95% CI P value Adjusted 
hazard 
ratio  
95% CI P value 
Model 1       
Pure EEC 1   1   
Mixed EEC-SC 1.392 0.583-3.324 0.456 1.208 0.471-3.098 0.695 
Pure SC 3.896 1.973-7.694 <0.001 3.444 1.721-6.894 <0.001 
       
Model 2       
Pure EEC 0.257 0.130-0.507 <0.001 0.290 0.145-0.581 <0.001 
Mixed EEC-SC 0.357 0.132-0.969 0.043 0.351 0.120-1.022 0.055 
Pure SC 1   1   
       
Overall survival Unadjusted 
hazard 
ratio 
95% CI P value Adjusted 
hazard 
ratio  
95% CI P value 
Model 1       
Pure EEC 1   1   
Mixed EEC-SC 2.358 0.932-5.968 0.070 1.970 0.726-5.345 0.183 
Pure SC 4.831 2.099-11.116 <0.001 3.462 1.474-8.131 0.004 
       
Model 2       
Pure EEC 0.207 0.090-0.476 <0.001 0.289 0.123-0.678 0.004 
Mixed EEC-SC 0.488 0.169-1.415 0.187 0.569 0.182-1.777 0.332 
Pure SC 1   1   
 
Cox regression analysis, whether or not adjusted for age and FIGO stage, was used to evaluate differences in 
RFS and OS in the three patient groups. In model 1, pure EEC was used as a reference, in model 2, pure SC was 
used as reference. Abbreviations: EEC: endometrioid endometrial cancer; SC: serous endometrial cancer. 
 
 Table 3. Number of pure EEC, mixed EEC-SC and pure SC carrying at least 1 mutation in the indicated 
genes. 
 
 
 
 
 
 
 
 
 
KRAS, PIK3CA, PTEN, and TP53, mutation frequencies respectively in pure EEC, mixed EEC-SC, and pure SC. 
Abbreviations: EEC, endometrioid endometrial carcinoma; Mixed EEC-SC: mixed endometrioid serous 
carcinoma; SC: Serous carcinoma. P values of a Pearson’s chi square test are given.  
 
 
 Pure EEC 
n=230 
mixed EEC-SC 
n=23 
Pure SC 
n=24 
P value 
Χ2 
     
KRAS 
 
39 (17.0%) 6 (26.0%) 3 (12.5%) 0.439 
PIK3CA 
 
31 (13.5%) 6 (26.0%) 4(16.7%) 0.258 
     
     
TP53 
 
4 (1.7%) 5 (22%) 4 (16.7%) <0.001 
PTEN 
 
45 (19.6%) 3 (13.0%) 0  0.047 
     
Table 4. Hotspot mutation frequencies in separate components of mixed EEC-SC and pure EEC and pure 
SC. 
KRAS, PIK3CA, PTEN, and TP53, mutation frequencies respectively in pure EEC, mixed EEC-SC, and pure SC. 
Abbreviations: EEC, endometrioid endometrial carcinoma; Mixed EEC-SC: mixed endometrioid serous 
carcinoma; SC: Serous carcinoma. 
pure EEC 
n=230 
EEC component in 
mixed EEC-SC 
n=23 
SC component in 
mixed EEC-SC 
n=23 
pure SC 
n=24 
KRAS 39 (17.0%) 5 (21.7%) 4 (17.4%) 3 (12.5%) 
PIK3CA 31 (13.5%) 6 (26.0%) 6 (26.0%) 4 (16.7%) 
TP53 4 (1.7%) 3 (13.0%) 4 (17.4%) 4 (16.7%) 
PTEN 45 (19.6%) 3 (13.0%) 2 (8.7%) 0 
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